This example paper analyzes a challenging ethical dilemma faced by a healthcare administrator regarding patient data privacy versus public health concerns during an outbreak. It demonstrates how to structure an argument, use evidence effectively, and maintain an objective yet persuasive tone. The analysis breaks down the paper's claim, organizational strategy, and potential revision points, offering practical insights for students and professionals developing their own ethical decision-making essays.
Structure your ethical decision-making paper logically: define the dilemma, apply frameworks, analyze stakeholders, propose a solution, and justify it.
Clearly articulate your central claim or thesis regarding the most ethical course of action.
Use established ethical frameworks (e.g., utilitarianism, deontology, justice) as analytical tools, explaining how they apply to the specific scenario.
Acknowledge and weigh the interests of all relevant stakeholders to demonstrate a comprehensive understanding of the issue.
Assignment brief
Imagine you are a mid-level manager in a large pharmaceutical company. Your team has developed a new drug that shows significant promise for treating a rare but aggressive form of cancer. However, during the final stages of clinical trials, a small subset of participants (approximately 2%) experienced severe, potentially life-threatening side effects that were not initially anticipated. The data suggests these side effects are linked to a specific genetic marker present in that subset. The drug's efficacy for the majority of patients is undeniable, and it could save thousands of lives annually. The company is under immense pressure to release the drug quickly due to market demand and competitor activity. Write a paper analyzing the ethical considerations involved in the decision to release, delay, or modify the drug's release. Your analysis should identify the primary ethical frameworks applicable, weigh the competing stakeholder interests, and propose a course of action with clear justification.
Reference example
The decision regarding the release of RX-7, a novel oncological therapeutic, presents a profound ethical quandary, demanding careful consideration of competing values and stakeholder interests. At its core, this situation pits the imperative to alleviate suffering and save lives against the fundamental duty to prevent harm and ensure patient safety. The drug's demonstrated efficacy for the vast majority of patients suffering from a rare, aggressive cancer cannot be understated; it offers a beacon of hope where little previously existed. Yet, the emergence of severe, unanticipated side effects in a small but identifiable patient subset necessitates a rigorous ethical evaluation before market introduction.
Several ethical frameworks offer lenses through which to analyze this dilemma. Utilitarianism, which advocates for actions that produce the greatest good for the greatest number, might initially favor rapid release. The potential to save thousands of lives annually, weighed against the severe but statistically rare adverse events, could lead to the conclusion that the net benefit is overwhelmingly positive. However, a strict utilitarian calculus must also account for the severity of the harm experienced by those affected, the potential for long-term societal distrust in pharmaceutical innovation, and the ethical weight of knowingly exposing a subset of patients to significant risk, even if small. This approach risks devaluing the well-being of the minority for the benefit of the majority.
Conversely, deontological ethics, emphasizing duties and rules, would focus on the inherent rightness or wrongness of actions, irrespective of their consequences. From this perspective, knowingly releasing a drug with potentially fatal side effects, even to a small group, could be seen as violating a fundamental duty to 'do no harm' (non-maleficence). The principle of informed consent, central to medical ethics, becomes particularly complex. While patients would be informed of the risks, the full extent and severity of these novel side effects might not be perfectly communicable or comprehensible, especially under the pressure of a life-saving treatment.
The principle of justice also demands attention. Is it just to withhold a potentially life-saving treatment from the many because of risks to the few? Or is it unjust to subject the few to disproportionate harm? The identification of a specific genetic marker offers a potential pathway toward a more nuanced application of justice, suggesting that risks might be mitigated through targeted screening and personalized treatment protocols. This aligns with the principle of distributive justice, which concerns the fair allocation of benefits and burdens.
Stakeholder analysis reveals a complex web of competing interests. Patients with the target cancer, particularly those with the identified genetic marker, face the most immediate and profound consequences. Their desire for a cure or effective treatment is paramount. Healthcare providers and regulatory bodies bear the responsibility of ensuring drug safety and efficacy, balancing therapeutic potential with risk management. The pharmaceutical company, driven by commercial imperatives and a mission to innovate, seeks to recoup substantial research and development investments and establish market leadership. Shareholders expect a return on investment, while the broader public has an interest in both access to innovative medicines and the integrity of the pharmaceutical industry.
Considering these frameworks and stakeholders, a strategy of immediate, unrestricted release appears ethically untenable due to the severe risks and the violation of non-maleficence. A complete withdrawal, while prioritizing absolute safety, would deny a critical treatment to thousands and represent a significant loss of scientific progress and investment. Therefore, a modified release strategy, contingent upon rigorous risk mitigation, appears to be the most ethically defensible path.
This strategy would involve several key components. First, the company must invest further resources into developing and validating a reliable genetic screening test to identify individuals with the specific marker associated with adverse reactions. Second, the drug's labeling and patient information materials must be updated to clearly and comprehensively communicate the identified risks, the genetic marker, and the necessity of pre-treatment screening. Third, a robust post-market surveillance system must be implemented, far exceeding standard protocols, to actively monitor for adverse events, collect real-world data, and rapidly identify any unforeseen issues. Fourth, the company should commit to ongoing research aimed at understanding the mechanism of the side effects and potentially developing countermeasures or alternative formulations.
This approach attempts to balance the competing ethical demands. It acknowledges the potential for significant benefit by allowing access to the drug for the majority of patients while actively working to protect the subset at risk. It upholds the principle of informed consent by ensuring patients are aware of specific, identifiable risks. It addresses justice by seeking to apply the drug equitably while managing risks proportionally. While this path involves additional costs and delays, it represents a more responsible and ethically sound course of action than either an immediate release or a complete withdrawal. The long-term viability and trustworthiness of pharmaceutical innovation depend on such careful, ethically grounded decision-making.
Analysis of the Ethical Decision-Making Paper
This paper tackles a complex ethical scenario common in scientific and corporate environments: the trade-off between potential benefit and identified risk in a new product. The author effectively structures the argument by first defining the core dilemma, then applying relevant ethical frameworks, analyzing stakeholder interests, and finally proposing a justified course of action. This systematic approach is crucial for demonstrating a thorough understanding of ethical reasoning and problem-solving.
Thesis and Claim
The central claim of the paper is that an immediate, unrestricted release of RX-7 is ethically indefensible, and a complete withdrawal is suboptimal. Instead, the author advocates for a 'modified release strategy' contingent upon rigorous risk mitigation, including genetic screening, enhanced informed consent, and robust post-market surveillance. This nuanced position acknowledges the drug's potential while prioritizing patient safety and ethical responsibility. The thesis is clearly articulated in the latter half of the paper, serving as the culmination of the preceding analysis.
Structure and Organization
The paper follows a logical progression:
1. Introduction of the Dilemma: The opening paragraph clearly states the core conflict between therapeutic benefit and patient harm.
2. Application of Ethical Frameworks: The subsequent paragraphs systematically explore how Utilitarianism, Deontology, and Justice principles apply to the situation, highlighting the strengths and weaknesses of each in this context.
3. Stakeholder Analysis: A dedicated section identifies and discusses the competing interests of various parties involved (patients, company, regulators, etc.).
4. Proposed Solution: The paper moves from analysis to prescription, outlining a specific, multi-faceted modified release strategy.
5. Justification: The concluding paragraphs defend the proposed solution by explaining how it balances the competing ethical demands and stakeholder needs.
This structure ensures that the argument builds progressively, moving from theoretical considerations to practical recommendations.
Use of Evidence and Reasoning
While this is a hypothetical scenario, the paper demonstrates strong reasoning by referencing established ethical principles and frameworks. The 'evidence' here is the logical application of these principles to the specific facts of the case. For instance, the discussion of Utilitarianism weighs 'greatest good' against 'severity of harm,' and deontology focuses on the duty to 'do no harm.' The identification of the genetic marker serves as a crucial piece of factual information that enables a more sophisticated ethical argument, moving beyond a simple binary choice. The reasoning is sound, connecting the abstract principles to the concrete details of the pharmaceutical release decision.
Tone and Style
The tone is appropriately academic, objective, and measured. The author avoids overly emotional language, even when discussing severe side effects or life-saving potential. Phrases like 'profound ethical quandary,' 'rigorous ethical evaluation,' and 'ethically defensible path' contribute to a formal and analytical style. The use of contractions is avoided, and sentence structure is varied, maintaining reader engagement while conveying complex ideas clearly. The overall impression is one of careful deliberation and reasoned judgment.
Revision Opportunities
Quantification: While the paper discusses 'thousands of lives' and 'small subset,' adding hypothetical (but realistic) numbers could strengthen the utilitarian analysis (e.g., 'estimated 5,000 lives saved annually vs. 100 individuals experiencing severe side effects').
Specific Frameworks: While Utilitarianism, Deontology, and Justice are mentioned, exploring other relevant frameworks like Virtue Ethics (what would a virtuous pharmaceutical company do?) or Principlism (autonomy, beneficence, non-maleficence, justice) could add further depth.
Counterarguments: Explicitly addressing and refuting potential counterarguments to the proposed modified release strategy (e.g., the cost and feasibility of widespread genetic screening, the potential for patient anxiety due to screening results) would bolster the argument.
Company Culture: Briefly touching upon how the company's existing ethical culture or policies might influence or be influenced by this decision could add another layer of analysis.
Example of Applying a Framework
Consider the application of the principle of non-maleficence. The paper states, 'a strict utilitarian calculus must also account for the severity of the harm experienced by those affected.' This demonstrates an understanding that even if the probability of harm is low, its severity can significantly impact the ethical calculus. A more detailed explanation might read: 'The principle of non-maleficence, often summarized as 'do no harm,' is directly challenged by the known severe side effects. While utilitarianism might permit such harm if outweighed by greater good, deontological ethics and principles of medical ethics place a strong emphasis on avoiding direct harm. The severity of these side effects—potentially life-threatening—means that even a small incidence rate cannot be ethically dismissed without substantial justification and mitigation efforts.'
FAQs
What are the most common ethical frameworks used in decision-making papers?
Commonly used frameworks include Utilitarianism (focusing on outcomes and the greatest good), Deontology (focusing on duties, rules, and rights), Virtue Ethics (focusing on character and moral virtues), and Principlism (often used in bioethics, emphasizing autonomy, beneficence, non-maleficence, and justice). You should select frameworks that best suit the specific ethical dilemma you are analyzing.
How much detail should I include about the potential negative consequences?
You should provide enough detail to clearly illustrate the ethical stakes involved. For instance, if discussing risks, specify the nature and severity of the potential harm. If discussing benefits, quantify them where possible. The goal is to provide a concrete basis for your ethical evaluation, allowing readers to understand the gravity of the choices being made.